Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results
Xenetic Biosciences, a biopharmaceutical company focused on advancing immune-oncology technologies addressing hard-to-treat cancers, has entered into a manufacturing agreement with Catalent Pharma Solutions, which will include cGMP manufacturing for the company's recombinant protein, Human DNase I.